A Phase I trial of CS1003 to assess the drug safety in patients with advanced cancers.
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs CS-1003 (Primary)
- Indications Cancer
- Focus Adverse reactions
- 02 Jan 2018 New trial record
- 27 Dec 2017 According to a CStone pharmaceuticals media release, a formal application for clinical trial approval has been submitted to Human Research Ethics Committees of the Scientia Clinical Research center in Australia.